HER-2 therapy. HER-2/neu diagnostics in breast cancer

Walter P. Carney, Kim Leitzel, Suhail Ali, Rainer Neumann, Allan Lipton

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations


HER-2/neu status of the primary breast cancer (PBC) is determined by immunohistochemistry and fluorescent in situ hybridization. Because of a variety of technical factors, however, the PBC may not accurately reflect the metastatic tumor in terms of HER-2/neu status. Recently published guidelines recommend that tumors be defined as HER-2/neu positive if 30% or more of the cells are 3+. Circulating levels of the HER-2 extracellular domain can be measured in serum using a test cleared by the US Food and Drug Administration, and increased serum HER-2/neu levels to above 15 ng/ml can reflect tumor progression. Studies comparing tissue HER-2/neu status of the PBC and HER-2/neu levels above 15 ng/ml in metastatic breast cancer patients are also reviewed.

Original languageEnglish (US)
Article number207
JournalBreast Cancer Research
Issue number3
StatePublished - Jun 4 2007

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'HER-2 therapy. HER-2/neu diagnostics in breast cancer'. Together they form a unique fingerprint.

Cite this